Join leading experts as they discuss the evolving role of immunotherapy in limited-stage small cell lung cancer (LS-SCLC). This on-demand activity covers guideline-recommended treatments, the therapeutic rationale for PD-L1 immune checkpoint inhibitors, and the latest clinical trial evidence. Through real-world case studies, gain actionable insights into designing treatment strategies and managing immunotherapy-related adverse events. Don’t miss this opportunity to enhance your understanding of how to integrate cutting-edge data into patient care for LS-SCLC.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/latest-clinical-evidence-immunotherapy-small-cell-lung-cancer-booster-quiz-on
- Start Date: 2025-01-31 06:00:00
- End Date: 2025-01-31 06:00:00
- Credit Details: IPCE Credits: 0.5 hours
AAPA Category 1 Credit™️: 0.5 hours
AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours
Pharmacy: 0.5 hours - Commercial Support: Source: AstraZeneca (Any division) - Amount: 35000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest